Darolutamide

Last Updated: 11/08/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 558 publications

Establishment and characterization of LNCaP-TR-BoM, a bone metastasis-derived prostate cancer cell line with an intermediate AR-attenuated phenotype.

Establishment and characterization of LNCaP-TR-BoM, a bone metastasis-derived prostate cancer cell line with an intermediate AR-attenuated phenotype.

Journal: bioRxiv : the preprint server for biology
Published: October 25, 2026

Apalutamide-induced drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson syndrome overlap successfully treated with cyclosporine and benralizumab: A case report and literature review.

Apalutamide-induced drug reaction with eosinophilia and systemic symptoms and Stevens-Johnson syndrome overlap successfully treated with cyclosporine and benralizumab: A case report and literature review.

Journal: JAAD case reports
Published: October 22, 2026

EARLY DETECTION OF BONE METASTASIS BY WHOLE-BODY MRI AND TRIPLET THERAPY AFTER RADICAL PROSTATECTOMY: A CASE REPORT

EARLY DETECTION OF BONE METASTASIS BY WHOLE-BODY MRI AND TRIPLET THERAPY AFTER RADICAL PROSTATECTOMY: A CASE REPORT

Journal: Nihon Hinyokika Gakkai zasshi. The japanese journal of urology
Published: October 22, 2026

Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis.

Androgen receptor inhibitor double therapies in the management of metastatic castration-sensitive prostate cancer: a cost-effectiveness analysis.

Journal: Journal of medical economics
Published: October 07, 2026

Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone-sensitive prostate cancer: the ARASENS and LATITUDE trials.

Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone-sensitive prostate cancer: the ARASENS and LATITUDE trials.

Journal: BJU international
Published: October 05, 2026

AGRANULOCYTOSIS CAUSED BY APALUTAMIDE : A CASE REPORT

AGRANULOCYTOSIS CAUSED BY APALUTAMIDE : A CASE REPORT

Journal: Hinyokika kiyo. Acta urologica Japonica
Published: October 01, 2026

The emerging trends in prostate cancer treatment: a systematic review of the literature.

The emerging trends in prostate cancer treatment: a systematic review of the literature.

Journal: Journal of chemotherapy (Florence, Italy)
Published: August 20, 2026

Pharmacovigilance of Androgen Receptor Pathway Inhibitors in Prostate Cancer: The Impact of Docetaxel Co-Reporting.

Pharmacovigilance of Androgen Receptor Pathway Inhibitors in Prostate Cancer: The Impact of Docetaxel Co-Reporting.

Journal: Cancers
Published: August 20, 2026

AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?

AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?

Journal: Frontiers in oncology
Published: August 19, 2026

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer.

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer.

Journal: JAMA network open
Published: August 19, 2026

Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer.

Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer.

Journal: JAMA oncology
Published: August 13, 2026

Commentary on "matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC".

Commentary on "matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC".

Journal: Future oncology (London, England)
Published: August 08, 2026
Showing 1-12 of 558

Last Updated: 11/08/2026